Flanders Vaccine’s Symposium:
A new generation of Genetically Modified (GM) vaccines: How to overcome the hurdles from bench to practice?
March 19, 2019
FOD-WASO – Ernest Blerotstraat 1, 1070 Brussels
(located on the opposite of Pullman Hotel or exit ‘Hortaplein’ of the railway station Brussels South/Midi)
deadline March 5, 2019
To overcome the limitations of traditional vaccines, the development and use of novel types of vaccines, especially those based on GM technology, are being considered more frequently.
Although GM vaccines are endowed with unique and beneficial qualities, major regulatory -, safety – and other aspects need clarification.
- What are the Belgian regulatory guidelines for the development of these novel types of vaccines? Is there a difference with other national regulatory frameworks in European countries?
- What are the challenges encountered in the pre-clinical and clinical field?
- How can we guarantee the safety and effectiveness of GM vaccines?
- Is there an environmental risk associated with the use of GM vaccines?
Join this symposium and learn more about these current and interesting topics. A panel of experts will be happy to answer your questions and fuel the discussion.
12:15-13:00: Registration and Welcome lunch
13:00-13:10: Introduction by Prof. Corinne Vandermeulen, KU Leuven
13:10-13:40: Belgian regulatory framework and guidance on the use of genetically modified vaccines in a clinical setting
By Stephanie Mali, Center of Excellence for Vaccines, FAMHP, Katia Pauwels, Biosafety & Biotechnology unit, Sciensano & Florence Kauffmann, Global Medical Affairs manager, GSK
13:40-14:00: European Regulatory aspect of GM Vaccines
by Prof. Dr. Pieter Neels, consultant, IABS
14:00-14:15: Experiences from the pre-clinical field: yellow fever vaccine-PLLAV technology
by Dr. Kai Dallmeier, Research Expert Virology & Chemotherapy, Group Leader Molecular Vaccinology and Vaccine Discovery, KU Leuven
14:15-14:30: Experiences from the veterinary clinical field
by Dr. Melody Janssen, Virovet
14:30-15:00: COFFEE BREAK
15:00-15:20: Experiences from the clinical field
by Janssen Pharmaceutica
15:20-15:40: Experiences from the clinical field in Belgium
by Bruno Speder, Head Clinical Regulatory Affairs and Consultancy, SGS
15:40-16:20: Interactive Panel Discussion
16:20-16:30: Closing of the day by Prof Pierre Van Damme, UAntwerpen
16:30-17:30: Networking reception
Interactive Panel Discussion: Questions for the expert panel can be submitted to email@example.com until March 5, 2019. There will also be the possibility to ask your questions on the spot.
For REGISTRATION, click <<here>>
(registration is open until March 5, 2019)
Notifications received upon 2 weeks before the start of the event, get refunded for 100%. Cancellation requests received less than 2 weeks before the start of the event won’t be refunded. No-shows on the day of the event will not be refunded and are requested to pay the full fee. Replacement by a colleague is always allowed.